MaxCyte STx cell engineering platform

Electroporation is a non-viral transfection method that applies an electric pulse to cells to cause transient permeability in the cell membrane. Diverse genetic engineering payloads such as DNA, mRNA, sgRNA and RNPs can travel through the membrane and enter the cell. Electroporation is a highly efficient delivery method that can be applied to a variety of cell types, from insect to mammalian.

MaxCyte’s STx cell engineering platform is based on Flow Electroporation technology, a universal transfection technology designed for the high-performance delivery of virtually any molecule to any cell, at any scale. It has the ability to transfect primary cells, stem cells and cell lines with minimal cell disturbance and transfection efficiencies routinely >90% for a variety of cell types. The company says its technology allows scientists to use the most physiologically relevant system facilitating the identification, development and manufacturing of cell therapies, biotherapeutics and small molecule candidates of the highest quality.

The platform provides a scalable electroporation technology for high-yield expression of complex proteins, vaccines and biologics, with the ability to transfect anywhere from 75,000 to 20 billion cells. These higher yields save time and cost in the development pathway.

MaxCyte has evolved the electroporation process from a single cuvette experiment to a Flow Electroporation protocol suitable for genetic engineering at any scale. The complete workflow, from development to manufacturing, can be performed on a single platform, meaning there is no need for repeat optimisation and validation when progressing from concept to clinic. This results in accelerated timelines with the added benefit of reduced manufacturing cost. A safer and more rapid therapeutic development pipeline can expedite therapies to patients, saving lives.